Focal Therapy for Prostate Cancer

Preservation of Quality of Life

Focal therapy minimizes risks of common side effects such as urinary incontinence and erectile dysfunction by sparing healthy prostate tissue.

Lower Risk of Complications

Compared to surgery or whole-gland radiation, focal therapy is associated with reduced treatment-related morbidity and a quicker return to normal activities.

Targeted Cancer Control

By precisely treating only the cancerous lesions, focal therapy reduces damage to surrounding tissues while still achieving effective oncological outcomes.

Repeatable and Salvageable

In cases of recurrence, focal therapy can often be safely repeated, and patients retain the option to undergo other treatments such as surgery or radiation if needed.

Focal therapy may be a suitable option for men with localized prostate cancer who are seeking a balance between effective cancer control and maintaining quality of life. Eligibility depends on several factors, including:

• Cancer location and size
• Cancer grade
• Imaging results
• Personal treatment preferences

A detailed assessment will determine whether focal therapy is appropriate for your specific case.

Dr Nicholas Mehan is one of Australia’s leading experts in focal therapy for prostate cancer. He was an investigator in the first in-human trial of interstitial cooled laser prostate ablation at Nepean Hospital and remains actively involved in ongoing research and innovation in this field.

As a high-volume focal therapy surgeon, Dr Mehan combines technical excellence with a strong commitment to education and training. He recently convened the Focal Therapy Masterclass at the Asia-Pacific Prostate Cancer Conference (APCC) 2025 and has been an invited speaker at several international meetings.

Dr. Mehan currently offers focal therapy at Chris O’Brien Lifehouse.